BMS revises hepatitis B therapy warning label

The FDA reports that Bristol-Myers Squibb has revised hepatitis B therapy Baraclude's boxed warning labeling to caution against its use in HIV/hepatitis B virus co-infected patients who are not also receiving highly active antiretroviral therapy due to the potential for developing HIV resistance.

You must be a registered member of MMM to post a comment.
close

Next Article in Legal/Regulatory